Thus, conceptually, the high level of inflammation seen in severe COPD with chronic bronchitis phenotype may be more responsive to an inhaled glucocorticoid and a PDE4 inhibitor if used together (Giembycz and Newton, 2015). Here, PDE4A is linked to chronic bronchitis.